Study to Evaluate the Safety and Efficacy of the Combination Therapy of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)

This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety, tolerability, efficacy and PK of the combination therapy of SCY-078 plus voriconazole compared to those of voriconazole monotherapy in male and female subjects 18 years of age and older with a hematological malignancy (HM) or a myelodysplastic syndrome or aplastic anemia or hematopoietic cell transplantation (HCT) and a probable or proven invasive pulmonary aspergillosis based on EORTCMSG criteria. In addition, all subjects must be positive (≥0.5) for serum GMI.

Antifungal name: 

Date of article/Start date of trial: 

Tuesday, January 22, 2019

Trial phase: 

Phase 2

ClinicalTrials.gov ID: 

NCT03672292

Trial status: 

Active
New antifungal drugs